The short version of Synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-04. Anything still debated is marked as such rather than presented as settled.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
The full name often given is N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. This name indicates a chain containing tyrosine, isoleucine, and a six-carbon amino acid derivative. Databases list a CAS Registry Number and a molecular formula for the compound. The peptide is small compared with proteins, and its structure allows it to be studied in cell cultures and animal models. Exact identity depends on the supplier's synthesis and purification process. Minor impurities can remain after synthesis.
Chemically, dihexa belongs to a broader group of angiotensin IV analogs. Researchers have modified the natural peptide to alter stability, binding, or distribution. Such changes can affect how the molecule behaves in experiments. The parent peptide angiotensin IV is involved in various physiological processes, but the modified analog is not identical to it. Public summaries sometimes blur the distinction between the natural fragment and the synthetic research compound. This distinction matters when interpreting study results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Derived from an angiotensin IV sequence. |
| Appearance | White to off-white powder | Typical for lyophilized research peptides. |
| Solubility | Soluble in dimethyl sulfoxide; sparingly in water | Exact aqueous solubility depends on salt form and purity. |
| Typical storage temperature | -20 °C or below | Desiccated and protected from light for long-term storage. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary in catalog listings. |
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
In South Korea, most public universities are national. There are 29 national universities, eighteen special universities, and ten educational universities. In addition, there are two national colleges and the Korea National Open University which offers distance learning. The University of Seoul is a public municipal university.
== Structure and bonds == Conjugated proteins always have a prosthetic group that is highly associated with the polypeptide chain. Association can occur either through covalent bonding or strong noncovalent interactions like hydrogen bonding, ionic bonding, or coordination bonding. Depending on whether the prosthetic group is a carbohydrate or phosphate, covalent bonds would involve the formation of either glycoside linkage between the carbohydrate and amino acids or ester linkage between the phosphate residue and the protein.
In 1990 West Germany and East Germany jointly signed the Treaty on the Final Settlement with Respect to Germany (also known as the "Two-plus-Four Agreement"); by which transitional status of Germany following World War II was definitively ended and the Four Allied powers relinquished their joint residual sovereign authority for Germany as a whole including the area of West Berlin which had officially remained under Allied occupation for the purposes of international and GDR law (a status that the Western countries applied to Berlin as a whole despite the Soviets declaring the end of occupation of East Berlin unilaterally many decades before). The Two-plus-Four Agreement also saw the two parts of Germany confirm their post-war external boundaries as final and irreversible (including the 1945 transfer of former German lands east of the Oder–Neisse line), and the Allied Powers confirmed their consent to German Reunification. From 3 October 1990, after the reformation of the GDR's Länder, the East German states and East Berlin joined the Federal Republic.
==== MeSH D12.776.467.374.480 – lymphokines ==== MeSH D12.776.467.374.480.350 – interferon type ii MeSH D12.776.467.374.480.372 – interleukin-2 MeSH D12.776.467.374.480.428 – leukocyte migration-inhibitory factors MeSH D12.776.467.374.480.438 – lymphotoxin MeSH D12.776.467.374.480.615 – macrophage-activating factors MeSH D12.776.467.374.480.615.350 – interferon type ii MeSH D12.776.467.374.480.625 – macrophage migration-inhibitory factors MeSH D12.776.467.374.480.640 – neuroleukin MeSH D12.776.467.374.480.700 – suppressor factors, immunologic MeSH D12.776.467.374.480.750 – transfer factor
Sources: en.wikipedia.org
== Products and services == Therapeutic antibody discovery Cell-receptor monoclonal antibody development In vivo animal study-grade antibodies development Molecular modeling Antibody sequencing Anti-idiotype antibody production Anti-protein antibodies for pharmacokinetics studies Immunogenicity assays for reagents and controls Immunoassay development Ligand-binding assay analysis Drug potency assay analysis Cell bank storage Full technical and project management
On 14 January 2021, the US Department of Health and Human Services announced that the waiver would no longer be required to prescribe buprenorphine to treat up to 30 people concurrently. New Jersey authorized paramedics to give buprenorphine to people at the scene after they have recovered from an overdose.
=== Plaque psoriasis === Adalimumab has been shown to treat moderate to severe chronic plaque psoriasis in adults who have the condition in many areas of their body and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills). Adalimumab has been shown to be effective therapy when used either continuously or intermittently in patients with moderate to severe psoriasis.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied in preclinical research. It is often described as an angiotensin IV analog, but it is not an approved medicine. Public information comes mainly from laboratory work and commercial listings.
No major regulatory agency has approved dihexa as a therapeutic product. Human safety and efficacy data are limited. Its sale as a research chemical does not constitute approval for medical use.
Some animal and cell studies report synaptic or cognitive effects, which has led to nootropic framing online. These findings are preliminary and have not been confirmed in robust human trials. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide modeled on angiotensin IV. It is used in laboratory and animal research, not as an approved medicine. Human effects remain poorly characterized.